Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy

Paolo Morfino1 · Alberto Aimo1,2 · Vincenzo Castiglione1 · Carolina Gálvez-Montón3,4 · Michele Emdin1,2 · Antoni Bayes-Genis3,4,5

Accepted: 3 October 2022 / Published online: 11 October 2022 © The Author(s) 2022

Abstract
Cardiac fibrosis is characterized by the deposition of extracellular matrix proteins in the spaces between cardiomyocytes following both acute and chronic tissue damage events, resulting in the remodeling and stiffening of heart tissue. Fibrosis plays an important role in the pathogenesis of many cardiovascular disorders, including heart failure and myocardial infarction. Several studies have identified fibroblasts, which are induced to differentiate into myofibroblasts in response to various types of damage, as the most important cell types involved in the fibrotic process. Some drugs, such as inhibitors of the renin–angiotensin–aldosterone system, have been shown to be effective in reducing cardiac fibrosis. There are currently no drugs with primarily anti-fibrotic action approved for clinical use, as well as the evidence of a clinical efficacy of these drugs is extremely limited, despite the numerous encouraging results from experimental studies. A new approach is represented by the use of CAR-T cells engineered in vivo using lipid nanoparticles containing mRNA coding for a receptor directed against the FAP protein, expressed by cardiac myofibroblasts. This strategy has proved to be safe and effective in reducing myocardial fibrosis and improving cardiac function in mouse models of cardiac fibrosis. Clinical studies are required to test this novel approach in humans.

Keywords Fibrosis · Myocardium · Anti-fibrotic therapies · Heart failure · CAR-T cells

Fibrosis results from excessive deposition of extracellular matrix (ECM) proteins, especially type I and III collagen, between tissue parenchymal cells. There are conditions characterized by an activation of the pro-fibrotic pathways secondary to other disease mechanisms, such as neuroendocrine activation in heart failure (HF), and conditions in which the first cause of disease is the deposition of fibrous tissue, such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis [1, 2]. In both cases, fibrosis can lead to organ dysfunction.

Tissue repair mechanisms that lead to the development of fibrosis are activated by acute or chronic tissue damage. The inflammatory response can be intense depending on the type of damage; it favors the release of mediators and the migration of neutrophils, eosinophils, and macrophages to the injured site. Tissue fibroblasts and other mesenchymal cells are activated, differentiating into myofibroblasts, which are cells with contractile action and secreting activity of ECM elements, when stimulated by pro-fibrotic cytokines such as fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and transformant-β growth factor (TGF-β) [3]. Myofibroblasts may also acquire resistance to cell death stimuli [4]. At the same time, the expression of matrix metalloproteinases (MMPs) is reduced. MMPs are mainly responsible for the replacement and degradation of ECM proteins [5].

Myocardial fibrosis is traditionally distinguished into “reparative” or “reactive” (Fig. 1). Reparative fibrosis is the replacement of necrotic cardiomyocytes following events of acute and extensive tissue damage, such as myocardial infarction (MI) or myocarditis. Other forms of myocardial
damage result in reactive fibrosis, with peculiar ECM structure and composition depending on the pathogenic cause of damage (Fig. 2). For example, pressure overload is characterized by perivascular fibrosis and interstitial fibrosis due to the activation of pro-fibrotic pathways (angiotensin II and endothelin 1) [6, 7]. The two forms of fibrosis often develop together within the same disease: reparative fibrosis following MI represents the immediate tissue response to damage; then, hormonal and paracrine activation trigger the reactive fibrosis in remote regions at MI, leading to post-infarction ventricular remodeling [8]. Myocardial fibrosis also slows the conduction of the cardiac action potential and predisposes to conduction disorders such as atrioventricular block [9]. Fibrotic regions also promote the generation of re-entry circuits and can trigger focal arrhythmias. In addition, myocardial fibrosis determines a chaotic and non-linear propagation of the action potential. Fibrotic infiltration in the atrium promotes the onset of atrial fibrillation (AF), as well as impairs the compliance and thus the mechanical properties of the atrium [10, 11]. In addition, atrial fibrosis may contribute to the development of atrial amyloidosis since the accumulation of amyloid substance is accompanied by the deposition of fibrous tissue, as observed in the ventricles [12, 13].

Histological analysis of endomyocardial biopsy samples with trichromatic and Sirius Red staining allows a direct evaluation of cardiac fibrosis [14, 15]. A non-invasive alternative for detecting myocardial fibrosis in vivo is cardiac magnetic resonance (CMR) imaging. Fibrotic regions are identified as late gadolinium enhancement areas. RMC also allows for the quantification of extracellular volume (ECV) [14, 16]. Regarding in vivo investigation techniques, the assay of circulating biomarkers of fibrosis is largely adopted. Among biomarkers of fibrosis, we can find collagen fragments and precursors, representing synthesis biomarkers; MMPs and MMP tissue inhibitors (TIMPs), representing degradation biomarkers; and galectin-3 and soluble tumor-2 suppressor [17]. However, recent studies show that the increase in plasma collagen biomarkers does not really reflect the extent of myocardial fibrosis, suggesting that new studies are needed for the validation of fibrosis biomarkers [18].

The amount of cardiac fibrosis has an important clinical and prognostic value. For example, there is a relationship between fibrotic extension in the left atrium at CMR and the efficacy of transcatheter ablation in patients with AF, with a greater recurrence of AF in subjects showing a larger pre-ablation fibrotic area [19]. In subjects with hypertrophic cardiomyopathy, the presence of fibrosis at CMR led to a 3.4-fold higher risk of mortality or hospitalization due to cardiovascular causes or implantation of cardioverter-defibrillator, with a 15% increase in risk as a result of a 5% increase in fibrosis; whereas in subjects with acute coronary syndrome the presence of cardiac fibrosis at CMR is strongly associated with sudden cardiac death [20, 21]. For these reasons, myocardial fibrosis can be considered an important therapeutic target.

Some drugs, such as renin–angiotensin–aldosterone system (RAAS) inhibitors, have been shown to be effective in reducing ECM deposition in the myocardium. However, no primarily anti-fibrotic medications have been approved for the treatment of cardiovascular disease.
Studies on animal models have revealed a wide variety of effective molecules in the treatment of fibrosis, but there is still no evidence of clinical benefit (Table 1). Recently, the first results from the phase II clinical trial PIROUETTE (The Efficacy and Safety of Pirfenidone in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction) show that pirfenidone may be effective and safe in patients with HF and preserved ejection fraction (FE) [23]. Anti-fibrotic T-cell therapy with chimeric antigen receptor (CAR) is widely used in oncology. Recent studies on preclinical models also encourage their potential use in cardiovascular diseases [24].

This literature review summarizes the possible options to target myocardial fibrosis, including the new perspective of CAR-T cell therapy.

**Drugs with no primarily anti-fibrotic role**

**RAAS inhibitors**

Angiotensin II (Ang II) binding Ang II type 1 receptors (AT1R) promotes collagen synthesis [25]. In chronic heart disease, there is generally a significant activation of RAAS, which is directly associated with the development of cardiac fibrosis [26]. Various studies have shown that both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) significantly reduce myocardial fibrosis regardless of their hypotensive effect. In a sample of hypertensive patients treated with lisinopril ($n = 18$), endomyocardial biopsy at 6 months revealed a significant reduction in collagen...
Table 1  Main evidence of anti-fibrotic drugs from clinical studies

| Study                          | Therapy     | Follow-up | Included patients (n) | Main evidence                                                                 |
|-------------------------------|-------------|-----------|-----------------------|-------------------------------------------------------------------------------|
| **RAAS inhibitors**           |             |           |                       |                                                                               |
| Brilla et al. [27]            | Lisinopril  | 6 months  | 35                    | Lisinopril reduces CVF in hypertensive patients compared with hydrochlorothiazide diuretic |
| López et al. [28]             | Losartan    | 12 months | 37                    | Losartan reduces CVF and PICP in hypertensive patients compared with amlodipine |
| Díez et al. [29]              | Losartan    | 12 months | 19                    | Losartan reduces CVF and LV stiffness in hypertensive patients with severe fibrosis |
| Shimada et al. [30]           | Losartan    | 12 months | 20                    | Losartan reduces fibrotic progression in patients with nonobstructive hypertrophic CMP |
| Kosmala et al. [32]           | Spironolactone | 6 months | 80                    | ACEi and spironolactone reduce PICP and PIINP in patients with metabolic syndrome compared with ACEi alone |
| Kosmala et al. [33]           | Spironolactone | 6 months | 113                   | Spironolactone improves myocardial deformation and reduces PICP and PIINP in obese patients with mild diastolic dysfunction |
| Mak et al. [34]               | Eplerenone  | 12 months | 44                    | Eplerenone reduces PIINP and slightly improves diastolic function in patients with diastolic HF |
| Deswal et al. [35]            | Eplerenone  | 6 months  | 44                    | Eplerenone reduces PINP and PICP in patients with HFpEF                        |
| Zannad et al. (post-hoc analysis RALES trial) [36] | Spironolactone | 6 months | 261                   | Spironolactone reduces PICP, PINP, and PIINP in patients with HFpEF             |
| Iraqi et al. (post hoc analysis EPHESUS trial) [38] | Eplerenone | 6 months | 476                   | Eplerenone reduces PINP and PIINP in patients with post-MI diastolic HF       |
| Ravassa et al. (post hoc analysis ALDODHF trial) [39] | Spironolactone | 12 months | 381                   | Spironolactone reduces PICP and improves diastolic function in patients with HFpEF. Patients with CITP/MMP-1 < 2.5 show less benefit from treatment |
| Cunningham et al. (post hoc analysis PARAMOUNT trial) [45] | Sacubitril/valsartan | 16 weeks | 1113                  | Sacubitril/valsartan reduces TIMP-1, sST2, and PIINP and increases CITP in HFpEF patients compared to valsartan alone |
| **Inflammation modulators**   |             |           |                       |                                                                               |
| RENEWAL trial [47]            | Etanercept  | 6 months  | 2356                  | Etanercept does not impact on mortality and hospitalizations in patients with HF |
| ATTACH trial [48]             | Infliximab  | Discontinued | 150                | Infliximab increases mortality in patients with HF                            |
| COLCOT trial [53]             | Colchicine  | 22.6 months | 4745               | Colchicine reduces the risk of ischemic cardiovascular events in patients with MI to 30 days |
| COVERT-MI [55]                | Colchicine  | 3 months  | 192                   | Colchicine improves the size of the infarcted area after MI and increases the risk of thrombus in LV |
| Abulhul et al. [62]           | Atorvastatin | 6 months | 56                    | Atorvastatin reduces PIINP levels in patients with systolic HF and normal cholesterol |
volume fraction (CVF) compared to patients treated with hydrochlorothiazide diuretic (n = 17) [27]. In a study with hypertensive patients treated with losartan (n = 21) and amlodipine (n = 16) with 1-year follow-up, the first group showed reduction of the collagen fraction and the carboxy-terminal pro-peptide of type 1 pro-collagen (PICP) [28]. Another study showed the effectiveness of losartan in reducing CVF and increasing left ventricular (LV) compliance to 1 year, but only in patients with severe fibrosis (CVF > 6%, n = 7) [29]. A further study showed attenuation in the progression of cardiac fibrosis in patients with nonobstructive hypertrophic cardiomyopathy treated with losartan [30].

Aldosterone, whose production is stimulated by Ang II, also exerts a pro-fibrotic effect in the myocardium by interacting with mineralocorticoid receptors [31]. Aldosterone receptor antagonists (spironolactone, canrenone, and eplerenone) showed significant anti-fibrotic effects. In 80 patients with metabolic syndrome treated with ACE inhibitors (ACEi), treatment with spironolactone for 6 months improved diastolic function and decreased levels of PICP and amino-terminal pro-peptide of type III pro-collagen (PIIINP) [32]. Similar results were obtained in another study which included 113 patients with obesity and mild diastolic dysfunction [33]. In 44 patients with HF with preserved EF (HFpEF), the administration of eplerenone for 12 months reduced PIIINP levels and resulted in a modest improvement in diastolic function [34]. Similar results emerged in a study showing that eplerenone reduced the PINP and PIIINP levels in 44 patients with HFpEF [35]. In the RALES study (Randomized Aldactone Evaluation Study), conducted in patients with HF with reduced EF (HFrEF), spironolactone was associated with reduced mortality and hospitalization, as well as with reduction in blood levels of fibrosis biomarkers and collagen synthesis [36, 37]. In a sub-analysis of the study EPHESUS (the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study), which evaluated the effect of eplerenone in patients with HF after MI (n = 476), treatment with eplerenone showed a significant reduction in plasma levels of PINP and PIIINP (p < 0.007 at 6 months for both), although these were not associated with prognostic events (mortality and hospitalization) [38]. Treatment with eplerenone (25 mg/day up to 50 mg/day, treated n = 3313, placebo n = 3319) was
also associated with a reduction in the risk of mortality and hospitalization for all causes (relative risk (RR): 0.92; 95% CI: [0.86; 0.98]; \( p = 0.02 \) after 16 months in treated patients with MI complicated by subsequent LV and cardiac dysfunction compared to controls [38]. A sub-study of the ALDODHF trial (The Aldosterone Receptor Blockade in Diastolic Heart Failure), which included 381 patients with HFP EF, identified that treatment with spironolactone reduces PICP levels and improves diastolic function after 12 months of treatment [39].

Several studies also highlight that the type B natriuretic peptide (BNP) plays an anti-fibrotic role through the interaction with its NPR-A and NPR-B receptors and subsequent activation of cGMP-dependent kinase (PKG) [40]. Although the role of the cGMP pathway in fibrosis is not fully understood, several preclinical studies have shown that an increase in PKG levels plays an anti-fibrotic effect through negative interference with the TGF-β pathway, which plays a crucial role in the activation of fibroblasts [41–44]. The administration of sacubitril/valsartan, which represents an association of ARB and an inhibitor of nephrin, which is the BNP degradation enzyme, has been shown to be effective in reducing fibrosis. PARAMOUNT (Prospective Comparison of ARNI With ARB on Management of Heart Failure with Preserved Ejection Fraction) trial showed that treatment with sacubitril/valsartan leads to the reduction of plasma biomarkers of cardiac fibrosis in patients with HFP EF [45].

Sixteen weeks after administration, the treatment group showed a reduction in plasma levels of TIMP-1 (8%; 95% CI: [6; 10%]; \( p < 0.001 \)), soluble suppression of tumorigenicity 2 (sST2) (4%; 95% CI: [1; 7%]; \( p = 0.002 \)) and PIIINP (3%; 95% CI: [0; 6%]; \( p = 0.04 \)), and an increase in carboxy-terminal telopeptide of type I collagen (CITP) (4%; 95% CI: [1 to 8%]; \( p = 0.02 \)), compared to patients treated with valsartan alone. This additional benefit seems to be caused by the increase in BNP levels [45].

**Inflammation modulators**

Tissue damage triggers a phlogistic process that triggers the deposition of fibrotic tissue. Tumor necrosis factor α (TNF-α) plays an important role in stimulating cardiac fibrosis [46]. However, the RENEWAL (Randomized etanercept Worldwide evaluation) study, which evaluated the effect of the TNF-α antagonist etanercept in patients with HF, showed no benefit in terms of mortality and hospitalization [47]. The ATTACH (anti-TNF Therapy Against Congestive Heart failure) study was prematurely discontinued due to increased mortality in patients with HF on infliximab, a TNF-α antagonist [48]. The later discovery that TNF-1 and TNF-2 receptors have opposite effects on cardiac remodeling may partly explain the disappointing results of TNF-α inhibition [49].

Colchicine has an important anti-inflammatory action because of its effectiveness in inhibiting inflammasome network, various pro-inflammatory cytokines and chemokines [50]. In mouse models of MI, colchicine has been shown to be effective in reducing the extent of the infarcted area. The reduction in the extent of fibrosis has been confirmed in a study on rabbit with HF [51, 52]. The COLCOT (COLCHICINE Cardiovascular Outcomes Trial) study, which randomized 4745 patients with MI to colchicine or placebo, revealed a lower risk of ischemic cardiovascular events at 30 days from MI in the treated group [53, 54]. The effect on myocardial fibrosis has not been specifically assessed. The recent COVERT-MI study (colchicine for Left ventricular Remodeling Treatment in Acute Myocardial Infarction) revealed that patients treated with colchicine after MI \( (n = 101) \) showed no difference in the size of the infarcted area at CMR compared to the controls \( (n = 91) \) [55].

Peroxisome-α proliferator-activated receptor (PPAR-α) agonists reduced myocardial fibrosis and improved cardiac function in animal models [56]. On the other hand, excessive expression of PPAR-α is associated with lipotoxicity, ventricular dysfunction, and cardiac hypertrophy [57, 58].

Besides reducing cholesterol levels, statins have a powerful anti-inflammatory and cardioprotective action by inhibiting the proteins Ras, Rho, and NF-kB, and activating the PI3K/Akt/Enos pathway [59, 60]. Rosuvastatin has been shown to be effective in attenuating cardiac fibrosis in mouse models of hypertensive heart disease [61]. In a small clinical study, therapy with 40 mg/day of atorvastatin for 6 months reduced PIIINP levels (4.65 ± 1.86 to 4.09 ± 1.25 ng/ml, \( p < 0.05 \)) in patients with systolic HF and normal cholesterol \( (n = 56) \) [62]. A study on hypertensive patients with atherosclerosis \( (n = 15) \) treated for the first time with 40 mg/day of atorvastatin for 12 weeks confirmed the effectiveness of the drug in reducing plasma levels of PIIINP (9.5 ± 2.7 to 6.4 ± 1.4 ng/ml, \( p = 0.012 \)) and TIMP-1 (299 ± 65 to 250 ± 45 ng/ml, \( p = 0.024 \)) [63]. Conflicting results were obtained in a sub-study of the UNIVERSE trial (The rosuvastatin Impact on VEntricular Remodeling cytokineS and neurohormonEs), in which an increase in plasma markers of collagen PINP \( (p = 0.03) \) and PIIINP \( (p = 0.001) \) was observed in patients with chronic HF \( (n = 32) \) treated for 6 months with rosvastatin titrated up to 40 mg/day [64]. In conclusion, the role of statins in the treatment of chronic HF is still controversial. Although several retrospective studies have revealed a better prognosis in patients with HF treated with statins, two randomized clinical trials, GISSI-HF (Italian Group for the Study of Survival in Heart Failure Failure) and CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure), reported no prognostic benefit from rosvastatin treatment in this class of patients [65, 66].
Overall, there is no clear evidence that anti-inflammatory drugs are effective in reducing cardiac fibrosis.

**Anti-TGF-β antibodies**

Transforming-β growth factor (TGF-β) has a central role in the development of cardiac fibrosis. TGF-β achieves its pro-fibrotic effect by the ALK/Smad2/3/Smad4, TAK/p-38/JNK, and NOX4/ROS signaling pathways (Fig. 3) [42, 67]. In mouse models of MI and hypertensive heart disease, anti-TGF-β and ALK5 antibodies led to reduction of myocardial fibrosis but not cardiomyocyte hypertrophy. However, anti-TGF-β antibody therapy has also been associated with serious adverse effects, including LV dilation and increased mortality [68, 69]. The blockade of the TGF-β signaling pathway through antibodies therefore seems dangerous, while less intense inhibition may be more effective.

**Pirfenidone**

Pirfenidone is an oral anti-fibrotic drug approved for the treatment of IPF [70, 71]. Since pulmonary and cardiac fibrosis share many pathophysiological mechanisms, there is an increasing interest in the application of pirfenidone in cardiovascular diseases [72]. The mechanism of action of pirfenidone remains to be elucidated, but it seems to reduce the expression of pro-fibrotic factors such as TGF-β and pro-inflammatory cytokines such as TNF-α, interleukin (IL)-4, and IL-13 [73]. Pirfenidone also promotes MMPs expression with subsequent reduction of ECM protein accumulation [74]. Pirfenidone could also contribute to the modulation of activation and proliferation of T and B cells, thus regulating the secretion of numerous pro-inflammatory and pro-fibrotic molecules, such as TNF-α and TGF-β [75–77].

![Fig. 3](image_url)

Fig. 3 Regulation of TGF-β signaling in cardiac fibrosis. Active TGF-β binds to type II and type I receptors, activating downstream Smad-dependent signaling cascades and Smad-independent pathways. TGF-β binding to the ALK5 type I receptor and downstream activation of Smad3 signaling induces a matrix-preserving program in cardiac fibroblasts and plays an important role in their activation following cardiac injury. In contrast, the role of ALK1/Smad1/5 signaling in regulation of fibroblast phenotype is poorly understood. Activation of Smad-independent pathways, including RhoA and MAPK signaling, mediates some of the effects of TGF-b in cardiac fibroblasts. Endogenous pathways for negative regulation of TGF-b cascades may protect from excessive or unrestrained fibrotic responses. The inhibitory Smads (Smad6/7), pseudoreceptors such as BAMBI, and soluble endoglin may serve as endogenous inhibitors of TGF-b signaling, limiting pro-fibrotic responses. Reprinted with permission from Frangogiannis [6]
In mouse models of hypertension, the administration of pirfenidone has been associated with reduced LV hypertrophy and increased survival compared to controls [78]. Another study documented that pirfenidone reduces ventricular remodeling and hinders interstitial fibrosis induced by Ang II infusion [79].

Only two retrospective studies evaluated the efficacy of pirfenidone on cardiac parameters in patients with IPF. In the first, no association between administration of pirfenidone and change in echocardiographic parameters was found [80]. In the second, pirfenidone was associated with a reduction in end-systolic and end-diastolic LV volumes, but without significant changes in ventricular function [81]. The PIR-OUETTE phase II study included 94 patients with HFpEF and extended fibrosis, defined as 27% ECV [23]. After a 52-week follow-up, an absolute reduction of 0.7% in the ECV in pirfenidone-treated group was found compared to 52-week follow-up, an absolute reduction of 0.5% in placebo-treated controls (p = 0.009). This very limited effect on the ECV was not associated with significant changes in diastolic function parameters [23].

MMP inhibitors

Although MMP inhibitors (MMPi) have been shown to attenuate cardiac fibrosis and remodeling in experimental models, these results have not achieved the expected clinical results [82, 83]. In the PREMIER (Prevention of Myocardial Infarction Early Remodeling) study, in which the effect of oral administration of PG-116800 in 253 patients with recent MI was evaluated, the drug has not shown any beneficial effect in preventing LV remodeling or improving the mortality rate or re-infarction at 90 days after MI [84].

Adrenergic receptor system modulators

Pharmacological blockade of β1 adrenergic receptors (β1-ARs) is a fundamental therapy for the treatment of HF and for the prevention of structural remodeling, preventing and attenuating progressive dilation of LV and cardiac hypertrophy [85–87]. In contrast, the signaling pathway of β2-AR plays anti-fibrotic effects. However, while the acute effect of β2-AR activation inhibits collagen synthesis, myofibroblasts extracted and isolated from patients with HF appear to be resistant to β2-AR agonists, possibly due to the increased activity of GPCR-2 kinase (GRK2) [88]. In fact, numerous studies on mouse models have highlighted the pathological role of GRK2 in HF. GRK2 became an attractive pharmacological target after the discovery that its inhibition is associated with significant protection against myocardial fibrosis in HF animal models [89]. In a pig model of post-MI HF, adeno-associated virus gene therapy allowed the expression of a GRK2 inhibitor peptide (βARKct), demonstrating long-term improvement of heart function [90]. Unlike β1- and β2-AR, β3-AR is thought to be resistant to desensitization because it lacks phosphorylation sites for GRK kinases [91]. Cardiac expression of β3-AR is physiologically low, but it increases in chronic disease conditions [92]. Evidence of the cardioprotective role of β3-ARs emerged from the demonstration that mice without β3-ARs experienced significant cardiac remodeling in response to transverse aortic constriction (TAC) [93]. β3-AR agonists (BRLs) have proven effective in counteracting cardiac fibrosis in several preclinical models of cardiovascular disease. In murine models of HFpEF induced by infusion of Ang II, the administration of BRLs has shown beneficial effects associated with attenuation of cardiac fibrosis, including improvement of myocardial stiffness and reduction of pulmonary congestion [94]. In mice knockout for neuronal nitric oxide synthase (nNOS) undergoing TAC, the administration of BRLs for 3 weeks revealed attenuation of ventricular dilation, systolic dysfunction, and partial reduction of cardiac hypertrophy [95]. However, the first randomized controlled trial that evaluated the effectiveness of the β3-AR mibefradil agonist in the HFrEF, namely, the BEAT-HF trial (Baroreflex Activation Therapy for Heart Failure), showed no improvement in cardiac function in terms of EF variation over a period of 6 months [96].

Anti-fibrotic therapy with CAR-T cells

Ex vivo engineered CAR-T cell therapy

CARs are engineered receptors that function to redirect lymphocytes, most commonly T cells, to recognize and eliminate cells expressing a specific target antigen. This interaction occurs in a specific CAR domain called “antigen binding domain” and allows endogenous activation of T cells, with subsequent elimination of target cells [97, 98]. CAR-T cell therapy represents a revolutionary therapeutic approach with significant and lasting clinical benefits already demonstrated in hematological diseases, such as large B-cell lymphoma or acute lymphoblastic leukemia (ALL) [99]. CAR-T cell therapy was approved by the Food and Drug Administration (FDA) in 2017 for the treatment of ALL [100].

Aghajanian et al. firstly investigated the effectiveness of ex vivo engineered T cells for the selective elimination of myofibroblasts expressing the fibroblast activation protein (FAP) on the membrane surface, in a mouse model of fibrosis induced by infusion of Ang II and phenylephrine [101]. The authors identified FAP as the best marker of cardiac myofibroblasts since peptide expression is almost exclusive to this cell population. The use of CAR-T cells directed against FAP resulted in the reduction of fibrosis in all seven treated mice, and an almost total elimination in 5/7, as well as the maintenance of normal systolic and
diastolic function [101]. A confirmation of the selectivity of CAR-T cells is provided by the persistence of perivascular fibrosis after treatment since perivascular fibroblasts do not expose FAP on the membrane surface and therefore do not represent a target for CAR-T FAP cells. In addition, the administration of engineered T cells in mice with fibrosis was shown to be safe and poorly cardiotoxic, with a very mild inflammatory response [101].

CAR-T cells are usually produced ex vivo by transduction using a retrovirus or lentivirus containing a DNA or RNA coding for a genetically modified CAR protein, in autologous T cells taken from the patient. Once modified, the T cells are expanded and infused into the patient with prior depletion of naïve T cells (Fig. 4) [102]. This method is effective but long and expensive. A further limitation of ex vivo engineered CAR-T cells is their persistent activation after infusion [103].

The most common reported adverse effect is the syndrome of release of pro-inflammatory cytokines by activated CAR-T cells and other immune cells, with an incidence of mild complications of 70–90% and severe complications, such as cardiogenic shock and multiorgan failure, equal to 20–50% [104, 105]. Potential toxicity associated with CAR-T cell therapy has stimulated the search for alternative approaches, such as the use of CAR-Natural Killer (NK) cells, and safer cell programming methods.

Use of CAR-T cells for the treatment of myocardial fibrosis in vivo

Rurik et al. developed a strategy to obtain anti-fibrotic transient CAR-T cells using a system of lipid nanoparticles (LNPs) that enclose modified mRNA [24]. The introduction of mRNA into T cells to transform them into CAR-T cells had already been performed through electroporation method, but exclusively ex vivo [106]. To avoid the need for extraction and reinfusion of T cells, the authors have developed an approach to achieve in vivo differentiation of CAR-T cells by infusion of LNP containing modified mRNA. The use of LNP-mRNA systems has been very successful in the production of vaccines against COVID-19 and in other clinical contexts since LNPs can be coated with antibodies directed against a specific target cell, such as T cells, to which they can be targeted.
release the mRNA [107]. The authors managed to produce CAR-T cells less stable and durable than that normally produced ex vivo, avoiding the problem of their indefinite permanence and activation.

Ex vivo production of CAR-T cells consists in the transduction with viral vector and the integration of a fragment of nucleic acid coding for the engineered CAR protein in the genome of the target cell. On contrast, the in vivo infusion through LNP-mRNA system leads to endocytosis of the LNP, resulting in the degradation and thus the release of mRNA, which is incapable of genomic integration and has a limited half-life, into the T cells' cytoplasm [24] (Fig. 5).

Rurik et al. first designed a modified mRNA coding for a CAR receptor directed against the FAP protein (FAPCAR), expressed by cardiac fibroblasts activated by tissue damage, and encapsulated it within an anti-CD5 antibody-coated LNP (CD5/LNP-FAPCAR). CD5 is a membrane glycoprotein physiologically expressed by T cells [108]. The authors subsequently tested the effectiveness of the CD5/ LNP-FAPCAR system in transforming a culture of T cells into CAR-T cells, and their ability to eliminate target cells with FAP expression in vitro. The positive results encouraged the translation of the method in vivo. Mice injected with Ang II and phenylephrine for 28 days then received intravenous administration of CD5/LNP-FAPCAR [109]. At 48 h after the injection, the authors detected a significant expression of FAPCAR in a portion (17.5–24.7%) of T cells (FAPCAR + /T), in the treated group [24]. Treated mice showed improved size, systolic and diastolic function, and LV mass compared to untreated mice [24] (Fig. 6).

Histological analysis showed a significant reduction in the ECM fraction, with regression of interstitial fibrosis, so that 5 of the 12 samples of treated mice were indistinguishable from sham animals [24].

Overall, the use of in vivo engineered CAR-T cells via LNP-mRNA and directed against FAP results in the elimination of cardiac myofibroblasts, in the reduction of myocardial fibrosis and improvement of cardiac geometry and function, potentially exceeding the limits of ex vivo engineering of CAR-T cells.

**Feasibility of CAR-T cell therapy in humans**

The infusion of CAR-T cells is emerging as a good approach to counteract cancer development and the number of potential targets suitable for CAR-T cell therapy is growing rapidly. The heart and the immune system are highly cross-linked and accumulating data suggest that the modulation of immunological cells may provide beneficial effects in many cardiovascular diseases, such as cardiac fibrosis, coronary atherosclerosis, and HF [110, 111]. The successful application of CAR-T cells to cancer treatment could be thus translated to other fields, making the CAR-T cells immunotherapy a potential approach against cardiovascular diseases.

However, there are still important limitations to CAR-T cell therapy that need to be solved. One of the most common limitations of CAR-T cell therapy in oncological disease is the development of the so-called antigen escape, which is the acquired tissue resistance to single antigen targeting. The cells of a significant portion of patients treated with CAR-T cells

---

**Fig. 5** In vivo production of CAR-T cells using CD5/LNP-FAPCAR. Administration of LNP coated with anti-CD5 antibodies and containing mRNA coding for the FAPCAR membrane receptor, which selectively recognizes the FAP protein expressed by cardiac myofibroblasts, allows to obtain transients CAR-T cells in vivo that specifically eliminate the pro-fibrotic cells from the injured myocardium. CAR, chimeric antigen receptor; FAP, fibroblast activation protein; LNP, lipid nanoparticle. Reprinted with permission from Rurik et al. [24]
may partly or completely lose the target antigen expression over time, thus eluding the CAR-T cells [112]. Moreover, CAR-T cell therapy is highly associated with life-threatening toxicities and cardiovascular events such as symptomatic heart failure, acute coronary syndrome, ischemic stroke, and de novo cardiac arrhythmia [113]. The toxic effects of CAR-T cells on cardiovascular system need to be further elucidated [113, 114]. In conclusion, new strategies are emerging, and they may provide a path forward more effective and safer future applications of CAR-T cell immunotherapy in cardiovascular diseases.

Conclusion

The pathophysiological heterogeneity of myocardial fibrosis and the complexity of tissue fibroblasts’ response to induced damage complicate the development of anti-fibrotic strategies in cardiovascular diseases. Some drugs have proven effective in reducing further deposition of ECM in the myocardium, such as RAAS inhibitors. Various purely anti-fibrotic strategies have performed promising results in preclinical models of cardiovascular disease. However, there is currently no anti-fibrotic drug that has clearly demonstrated
the regression of fibrosis and the health improvement in clinical trials. These results encourage the need for a new approach, potentially directed against the myofibroblasts, namely, the cells responsible for the fibrotic response, rather than on single molecular pathways. In vivo engineered CAR-T cells therapy is a novel approach, particularly promising for the treatment of pathological conditions characterized by an intense activation of pro-fibrotic pathways (such as MI or myocarditis). The effectiveness and safety of this approach should be verified in dedicated clinical trials.

ACEI angiotensin-converting enzyme inhibitor, CITP carboxy-terminal telopeptide of type I collagen, CMP cardiomyopathy, CVF collagen volume fraction, ECV extracellular volume, EF ejection fraction, IPF idiopathic pulmonary fibrosis, HFrEF heart failure with preserved ejection fraction, HFpEF heart failure with reduced ejection fraction, MI myocardial infarction, MMP matrix metalloproteinase, PICP carboxy-terminal pro-peptide of type I pro-collagen, PINP amino-terminal pro-peptide of type I pro-collagen, PIINP amino-terminal pro-peptide of type III pro-collagen, HF heart failure, sST2 soluble suppression of tumorigenicity 2, LV left ventricle, TIMP-1 tissue inhibitor of MMP-1.

Author contribution PM, AA: manuscript writing. VC, CG-M, ME, AB-G: manuscript revision.

Funding Open access funding provided by Scuola Superiore Sant’Anna within the CRUI-CARE Agreement.

Declarations

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Schellings MW, Pinto YM, Heymans S (2004) Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 64(1):24–31
2. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214(2):199–210
3. Zhao M, Wang L, Wang M et al (2022) Targeting fibrosis, mechanisms and clinical trials. Signal Transduct Target Ther 7(1):206
4. Kato K, Logsdon NJ, Shin YJ et al (2020) Impaired myofibroblast dedifferentiation contributes to nonresolving fibrosis in aging. Am J Respir Cell Mol Biol 62(5):633–644
5. Giannandrea M, Parks WC (2014) Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech 7(2):193–203
6. Frangogiannis NG (2021) Cardiac fibrosis. Cardiovasc Res 117(6):1450–1488
7. Zeisberg EM, Tarnavski O, Zeisberg M et al (2007) Endothelial-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13(8):952–961
8. Talman V, Ruskoaho H (2016) Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration. Cell Tiss Res 365(3):563–581
9. Nattel S, Shirotshi-Takeshita A, Cardin S et al (2005) Mechanisms of atrial remodeling and clinical relevance. Curr Opin Cardiol 20(1):21–25
10. Nguyen MN, Kiriazis H, Gao XM et al (2017) Cardiac fibrosis and arrhythmogenesis. Compr Physiol 7(3):1009–1049
11. Spach MS, Dolber PC, Heidlage JF (1989) Interaction of inhomogeneities of repolarization with anisotropic propagation in dog atria. A mechanism for both preventing and initiating reentry. Circ Res 65(6):1612–31
12. Vergaro G, Aimo A, Ravezzi C et al (2022) Atrial amyloidosis: mechanisms and clinical manifestations. Eur J Heart Fail Aug 3
13. Pucci A, Aimo A, Musetti V et al (2021) Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis. J Am Heart Assoc 10(20):e020358
14. de Boer RA, De Keulenaer G, Bauersachs J et al (2019) Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur J Heart Fail 21(3):272–285
15. Hinderer S, Schenke-Layland K (2019) Cardiac fibrosis – a short review of causes and therapeutic strategies. Adv Drug Deliv Rev 146:77–82
16. Iles L, Pfluger H, Phrommintikul A et al (2008) Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 52(19):1574–1580
17. Ding Y, Wang Y, Zhang W et al (2020) Roles of biomarkers in myocardial fibrosis. Aging Dis 11(5):1157–1174
18. Lopez B, Gonzalez A, Ravassa S et al (2015) Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 65(22):2449–2456
19. Oakes RS, Badger TJ, Kholmovski EG et al (2009) Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 119(13):1758–1767
20. O’Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):867–874
21. Zegard A, Okafor O, de Bono J et al (2021) Myocardial fibrosis as a predictor of sudden death in patients with coronary artery disease. J Am Coll Cardiol 77(1):29–41
22. Friedman SL (2012) Fighting cardiac fibrosis with CAR T cells. N Engl J Med 368(16):1576–1578
23. Lewis GA, Dodd S, Clayton D et al (2021) Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med 27(8):1477–1482
24. Rurik JG, Tombacz I, Yadegari A et al (2022) CAR T cells produced in vivo to treat cardiac injury. Science 375(6576):91–96
25. Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71(4):549–574
26. Schnee JM, Hsueh WA (2000) Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res 46(2):264–268
27. Brilla CG, Funck RC, Rupp H (2000) Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102(12):1388–1393
28. Lopez B, Querejeta R, Varo N et al (2001) Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardio reparative ability of antihypertensive treatment in hypertensive patients. Circulation 104(3):286–291
29. Diez J, Querejeta R, Lopez B et al (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105(21):2512–2517
30. Shimada YJ, Passeri JJ, Baggish AL et al (2013) Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart failure 1(6):480–487
31. Brilla CG, Zhou G, Matsubara L et al (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26(7):809–820
32. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H et al (2013) A randomized study of the beneficial effects of aldosterone antagonist on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovascular Imaging 4(12):1239–1249
33. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H et al (2013) Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart (British Cardiac Society) 99(5):320–326
34. Mak GJ, Ledwidge MT, Watson CJ et al (2009) Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 54(18):1674–1682
35. Deswal A, Richardson P, Bozkurt B et al (2011) Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Cardiac Fail 17(8):634–642
36. Zannad F, Alla F, Dousset B et al (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators Circulation 102(22):2700–2706
37. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England J Med 32;341(10):709–17
38. Iraqi W, Rossignon P, Angioi M et al (2009) Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119(18):2471–2479
39. Ravassa S, Trippel T, Bach D et al (2018) Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail 20(9):1290–1299
40. Hofmann F (2018) A concise discussion of the regulatory role of cGMP kinase I in cardiac physiology and pathology. Basic Res Cardiol 113(4):51
41. Matei AE, Beyer C, Gyori AH et al (2018) Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Ann Rheum Dis 77(3):459
42. Nakera K, Trojanowska M (2012) The role of TGF-beta receptors in fibrosis. Open Rheumatol J 6:156–162
43. Burke RM, Lighthouse JK, Mickelsen DM et al (2019) Sacubitril/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail 12(4):e005565
44. Kapoun AM, Liang F, O’Young G et al (2004) B-Type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94(4):453–461
45. Cunningham JW, Claggett BL, O’Meara E et al (2020) Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol 76(5):503–514
46. Sun M, Chen M, Dawood F et al (2007) Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115(11):1398–1407
47. Mann DL, McMurray JJ, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109(13):1594–1602
48. Chang ES, Packer M, Lo KH et al (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107(25):3133–3140
49. Hamid T, Gu Y, Ortuines RV et al (2009) Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation 119(10):1386–1397
50. Roubille F, Kritikou E, Busseuil D et al (2013) Colchicine: an old wine in a new bottle? Antiinflamm Antiallergy Agents Med Chem 12(1):14–23
51. Lampidis TJ, Kolonias D, Savaraj N et al (1992) Cardiotimulatory and antiarrhythmic activity of tubulin-binding agents. Proc Natl Acad Sci U S A 89(4):1256–1260
52. Akodad M, Faouconnier J, Sicard P et al (2017) Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model. Int J Cardiol 1(240):347–353
53. Tardif JC, Kouz S, Waters DD et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381(26):2497–2505
54. Akodad M, Sicard P, Faouconnier J et al (2020) Colchicine and myocardial infarction: a review. Arch Cardiovasc Dis 113(10):652–659
55. Mewton N, Roubille F, Bresson D et al (2021) Effect of colchicine on myocardial injury in acute myocardial infarction. Circulation 144(11):859–869
56. Ogata T, Miyauchi T, Sakai S et al (2004) Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 43(8):1481–1488
57. Sarma S (2012) Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits? Curr Mol Pharmacol 5(2):255–263
58. Oka S, Alicandro R, Zhai P et al (2011) PPARalp-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab 14(5):598–611
59. Yamamoto C, Fukuda N, Jumabay M et al (2011) Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with angiotensin II and high salt loading. Hypertens Res 34(3):348–353
60. Wolfrum S, Dendorfer A, Rikitake Y et al (2004) Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol

© Springer
3-kinase/protein kinase Akt and cardiovascular protection. Atheroscler Thromb Vasc Biol 24(10):1842–1847
61. Chang SA, Kim YJ, Lee HW et al (2009) Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension 54(3):591–597
62. Abuhul E, McDonald K, Martos R et al (2012) Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin Ther 34(1):91–100
63. Chang YF, Wu YW, Lee JK et al (2016) Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naive patients with hypertension with atherosclerosis. J Investig Med 64(7):1194–1199
64. Ashton E, Windebank E, Skiba M et al (2011) Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol 146(3):404–407
65. Kjekshus J, Apetrei E, Barrios V et al (2007) Rosuvastatin not improve cardiac remodeling in chronic heart failure? Lancet (London, England) 370(9645):1231–1239
66. Fang L, Murphy AJ, Dart AM (2017) A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol 8:186
67. Frantz S, Hu K, Adamek A et al (2008) Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103(5):485–492
68. Kuwahara F, Kai H, Tokuda K et al (2002) Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106(1):130–135
69. AlAnsari S, Southern B, Riaz H et al (2019) Responses to pirfenidone treatment in patients with idiopathic pulmonary fibrosis is not associated with changes in echocardiographic parameters of left ventricular structure and function. J Cardiac Fail 2019/08/01/;25(8, Supplement):S27
70. AlAnsari S, Southern BD, Sharma V et al (2020) Pirfenidone is associated with decreased indexed end diastolic and systolic volumes in patients with HFpEF and a known history of idiopathic pulmonary fibrosis. J Cardiac Fail 2020/10/01/;26(10, Supplement):S25
71. Heymans S, Lupu F, Terclavers S et al (2005) Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166(1):15–25
72. Matsuoka H, Ito T, Matsushima S et al (2006) Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47(4):711–717
73. Kuwahara F, Kai H, Tokuda K et al (2002) Transforming growth factor-beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103(5):485–492
74. Oku H, Shimizu T, Kawabata T et al (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary fibrosis biomarkers in statin-naive patients with hypertension with atherosclerosis. J Investig Med 64(7):1194–1199
75. Aimo A, Spitaleri G, Panichella G et al (2022) Pirfenidone as a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol Res 155:104694
76. Shibata T, Shimizu T, Kawai T et al (2012) Pirfenidone treatment in patients with idiopathic pulmonary fibrosis is not associated with changes in echocardiographic parameters of left ventricular structure and function. J Cardiac Fail 2019/08/01/;25(8, Supplement):S27
77. Aimo A, Cerbai E, Bartolucci G et al (2020) Pirfenidone is a novel cardiac protective treatment. Heart Fail Rev 27(2):525–532
78. Oku H, Shimizu T, Kawai T et al (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590(1–3):400–408
79. Shi Q, Liu X, Bai Y et al (2011) In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS ONE 6(11):e28134
80. Aimo A, Cerbai E, Bartolucci G et al (2020) Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol Res 155:104694
81. Visner GA, Liu F, Bizargity P et al (2009) Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation 88(3):330–338
82. Du J, Pu K, Flynn R et al (2017) Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production. Blood 129(18):2570–2580
83. Wang Y, Wu Y, Chen J et al (2013) Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology 126(1):1–11
84. Yamazaki T, Yamashita N, Izumi Y et al (2012) The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res 35(1):34–40
99. June CH, O'Connor RS, Kawalekar OU et al (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361–1365
100. Liu Y, Chen X, Han W et al (2017) Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc) 53(11):597–608
101. Aghajanian H, Kimura T, Rurik JG et al (2019) Targeting cardiac fibrosis with engineered T cells. Nature 573(7774):430–433
102. Sermer D, Brentjens R (2019) CAR T-cell therapy: Full speed ahead. Hematol Oncol 37(Suppl 1):95–100
103. Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 10;3(95):95ra73
104. Ghosh AK, Chen DH, Guha A et al (2020) CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC CardioOncol 2(1):97–109
105. Asnani A (2018) Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep 20(6):44
106. Zhao Y, Moon E, Carpenito C et al (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70(22):9053–9061
107. Pardi N, Hogan MJ, Porter FW et al (2018) mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discovery 17(4):261–279
108. Boumsell L, Coppin H, Pham D et al (1980) An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells. J Exp Med 1:152(1):229–34
109. Kaur H, Takefuji M, Ngai CY et al (2016) Targeted ablation of periostin-expressing activated fibroblasts prevents adverse cardiac remodeling in mice. Circ Res 118(12):1906–1917
110. Alvarez P, Briasoulis A (2018) Immune modulation in heart failure: the promise of novel biologics. Curr Treat Options Cardiovasc Med 20(3):26
111. Zayed MA (2020) Immune modulation of coronary atherosclerosis with anticytokine treatment. Circ Cardiovasc Imaging 13(9):e011451
112. Majzner RG, Mackall CL (2018) Tumor antigen escape from CAR T-cell therapy. Cancer Discov 8(10):1219–1226
113. Lefebvre B, Kang Y, Smith AM et al (2020) Cardiovascular effects of CAR T cell therapy: a retrospective study. JACC CardioOncol 2(2):193–203
114. Alvi RM, Frigault MJ, Fradley MG et al (2019) Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol 74(25):3099–3108
115. Schimmel K, Ichimura K, Reddy S et al (2022) Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target. Front Cardiovasc Med 9:886553

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.